Clinical Trials Logo

Necrosis clinical trials

View clinical trials related to Necrosis.

Filter by:

NCT ID: NCT06459895 Completed - Bronchial Asthma Clinical Trials

Biochemical Role of Long Non-coding RNA MALAT 1 and Serum Tumor Necrosis Factor Alpha in Bronchial Asthma Patients.

Start date: April 16, 2024
Phase:
Study type: Observational [Patient Registry]

Bronchial asthma affects more than a quarter of a billion people worldwide. It is responsible for over 1000 deaths a day, of which the majority are preventable (Levy, 2015). Asthma is a common heterogeneous disease characterized by chronic airway inflammation. It is defined by the history of variable respiratory symptoms, such as shortness of breath, chest tightness, wheezes, and cough, together with variable expiratory airflow limitation. Airflow limitation may later become persistent (GINA, 2023). The diagnosis of asthma is based on the history of these characteristic symptoms and evidence of variable expiratory airflow limitation from bronchodilator reversibility testing or other tests (GINA, 2023).

NCT ID: NCT06436352 Completed - Clinical trials for Femoral Neck Fractures

Does Capsulotomy in Closed Reduction of Femoral Neck Fractures Decrease Incidence of Avascular Necrosis?

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Femur's neck injuries are frequently encountered fractures. They are usually due to high energy or low energy indirect trauma. Healing of these fractures is usually hindered due to "avascular necrosis (AVN)" or "non-union" of the Femur's head. This study looks forward to investigating the impact of capsulotomy and internal fixation in lowering the incidence of complications and improving the functional outcomes.

NCT ID: NCT06433869 Recruiting - Malignant Ascites Clinical Trials

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Start date: December 14, 2023
Phase: Phase 2
Study type: Interventional

1. More than half of peritoneal metastases are from digestive tract. Peritoneal metastasis has poor prognosis, poor treatment response and limited means. 2. rmhTNF-NC or bevacizumab are effective in the treatment of malignant pleuroabdominal effusion. 3, There is increasing evidence that PD-1/PD-L1 inhibitors in combination with vascular endothelial growth factor receptor (VEGFR) inhibitors have a complementary mechanism of action: VEGF pathway inhibitors normalize blood vessels in tumors and promote immune cell maturation and infiltration, thus playing a synergistic role with ICIs. The strategy of systemic immunotherapy combined with antivascular therapy has been confirmed by several large phase III clinical trials such as IMbrave-150. Basic studies have confirmed that uncontrolled tumor vessels in peritoneal metastasis and malignant ascites microenvironment also play an important role in promoting disease progression. Therefore, this project intends to explore the treatment of malignant abdominal effusion by local intraperitoneal injection of bevacizumab and PD-1 on the basis of rmhTNF-NC

NCT ID: NCT06410079 Not yet recruiting - Femur Head Necrosis Clinical Trials

Difference in Return to Sports Activity After Hip Arthroplasty by THR or Resurfacing

PTH-50
Start date: June 1, 2024
Phase:
Study type: Observational [Patient Registry]
Read more »
NCT ID: NCT06388993 Recruiting - Hip Arthropathy Clinical Trials

Marrow Cellution™ vs. Traditional BMA Harvest Project

Start date: March 25, 2024
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT06347640 Recruiting - Clinical trials for Pulp Revascularization

Outcome of Pulp Revascularization of Necrotic Mature Permanent Teeth Using Platelet-rich Fibrin

Start date: April 1, 2023
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT06311331 Not yet recruiting - Clinical trials for Avascular Necrosis of the Talus

Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)

Start date: May 2024
Phase:
Study type: Observational

This is a Humanitarian Device Exemption (HDE) approved device. The purpose of this study is to evaluate the continued safety and probable benefit of the restor3d Total Talus Replacement device in commercial use.

NCT ID: NCT06310044 Not yet recruiting - Necrotic Pulp Clinical Trials

Effect of Commiphora Myrrh Solution as a Root Canal Irrigant on Post Operative Pain and Bacterial Load Reduction in Necrotic Tooth

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Clinically compare the post-operative pain , incidences post-operative swelling , post-operative number of analgesic tablets taken by patient and amount of bacterial load reduction after using 50% Commiphora Myrrh Chemomechanical preparation , versus 2.5% NaOCl,in asymptomatic necrotic mandibular premolar treated in single visit.

NCT ID: NCT06309095 Not yet recruiting - Clinical trials for Dental Pulp Necrosis

Investigation of the Effect of Low Torque and Speed on Post-Operative Pain After Root Canal Treatment

Start date: March 15, 2024
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT06256250 Active, not recruiting - Pulp Necroses Clinical Trials

Assessment of Post-operative Pain After Different Instrumentation Techniques in Pulpectomy Treatment of Primary Molars

Start date: August 10, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the post operative pain after using three different instrumentation techniques in pulpectomy treatment of pediatric participant. The main question it aims to answer: If different instrumentation techniques will affect the post operative pain in pulpectomy treatment of primary molars ? Participants will evaluate the pain using Modified Wong baker pain rating scale. Researchers will compare [ the adaptive XP endo shaper, Fanta AF baby files, and hand K files] to see if they will affect the post operative pain.